手机版 English 帮助中心
外文文献知网节
文献信息节点
基本信息 摘要 关键词 核心评价 相关文献
Journal | [J] 临床医学研究 Volume 6, Issue 3. 2024.
2 型糖尿病血管并发症的风险因素回顾及临床预测模型的应用
作者 : 李 贞林, 杨 卡明, 劳 琬文, 毕长 龙*
DOI: 10.12361/2705-0939-06-03-154718
全部来源
获取全文
摘要 / Abstract
2 型糖尿病目前已经成为一种严重威胁人类健康的疾病，根据国际糖尿病协会预测，到 2015 年，全世界糖尿病患 者数量将达到 4.15 亿，而到 2040 年将突破 6.4 亿。1、2 型糖尿病是一种很普遍的疾病，但是它与高致残率和高致死率密切 相关。其中，大血管病变包括心血管疾病、脑卒中及周围血管病变等，而小血管病变则包括神经病变、肾脏病及视网膜病变等。 目前，预测性建模已逐步发展为一种有效的辅助治疗手段，特别是对早期发现的病人，利用该方法可以极大地提升疾病的 诊断效果，节省费用。本文通过对当前已被认可的糖尿病血管并发症危险因子进行了回顾性总结，并对当前研究中的这些 预测模型的优缺点进行了比较。
关键词 / Keywords
2 型糖尿病；糖尿病并发症；风险因素；预测模型
Related articles / 相关文献
相似文献
作者发文
机构发文
关键词分析
相似文献（说明：与本文内容较接近的文献）
  • [1] FEDERATION. I D. IDF Atlas. 7th edition. [Z]. 2015.
  • [2] CHINESE DIABETES S. Guideline for the prevention
  • and treatment of type 2 diabetes mellitus in China(2020 edition) [J].
  • Chinese Journal of Endocrinology and Metabolism, 2021, 37(4):
  • 311-98.
  • [3] Global, regional, and national age-sex specific all_xfffe_cause and cause-specific mortality for 240 causes of death, 1990-
  • 2013: a systematic analysis for the Global Burden of Disease Study
  • 2013 [J]. Lancet, 2015, 385(9963): 117-71.
  • [4] FU J, PRASAD H C. Changing epidemiology of
  • metabolic syndrome and type 2 diabetes in Chinese youth [J]. Curr
  • Diab Rep, 2014, 14(1): 447.
  • [5] S C H E L L E N B E R G E S , D R Y D E N D M ,
  • VANDERMEER B, et al. Lifestyle interventions for patients with
  • and at risk for type 2 diabetes: a systematic review and meta_xfffe_analysis [J]. Ann Intern Med, 2013, 159(8): 543-51.
  • [6] BERGHEANU S C, BODDE M C, JUKEMA J W.
  • Pathophysiology and treatment of atherosclerosis : Current view
  • and future perspective on lipoprotein modification treatment [J].
  • Neth Heart J, 2017, 25(4): 231-42.
  • [7] ORMAZABAL V, NAIR S, ELFEKY O, et al.
  • Association between insulin resistance and the development of
  • cardiovascular disease [J]. Cardiovasc Diabetol, 2018, 17(1): 122.
  • [8] MOHAMMEDI K, WOODWARD M, HIRAKAWA Y,
  • et al. Presentations of major peripheral arterial disease and risk of
  • major outcomes in patients with type 2 diabetes: results from the
  • ADVANCE-ON study [J]. Cardiovasc Diabetol, 2016, 15(1): 129.
  • [9] SACKS D, BAXTER B, CAMPBELL B C V, et al.
  • Multisociety Consensus Quality Improvement Revised Consensus
  • Statement for Endovascular Therapy of Acute Ischemic Stroke [J].
  • Int J Stroke, 2018, 13(6): 612-32.
  • [10]MOHAMMEDI K, WOODWARD M, ZOUNGAS S,
  • et al. Absence of Peripheral Pulses and Risk of Major Vascular
  • Outcomes in Patients With Type 2 Diabetes [J]. Diabetes Care,
  • 2016, 39(12): 2270-7.
  • [11]CRIQUI M H, ABOYANS V. Epidemiology of peripheral
  • artery disease [J]. Circ Res, 2015, 116(9): 1509-26.
  • [12]CHENG B, JIANG Y, FU X, et al. Epidemiological
  • characteristics and clinical analyses of chronic cutaneous wounds
  • of inpatients in China: Prevention and control [J]. Wound Repair
  • Regen, 2020, 28(5): 623-30.
  • [13] VAN NETTEN J J, BUS S A, APELQVIST J, et al.
  • Definitions and criteria for diabetic foot disease [J]. Diabetes
  • Metab Res Rev, 2020, 36 Suppl 1: e3268.
  • [14] Rutherford's Vascular Surgery and Endovascular
  • Therapy, E-Book, 9th Edition 03-04-2018:
  • [15] BOUWMEESTER W, ZUITHOFF N P, MALLETT S,
  • et al. Reporting and methods in clinical prediction research: a
  • systematic review [J]. PLoS Med, 2012, 9(5): 1-12.
  • [16] RASMUSSEN A, ALMDAL T, ANKER NIELSEN A,
  • et al. Decreasing incidence of foot ulcer among patients with type
  • 1 and type 2 diabetes in the period 2001-2014 [J]. Diabetes Res
  • Clin Pract, 2017, 130: 221-8.
  • [17] GONG Q, ZHANG P, WANG J, et al. Morbidity and
  • mortality after lifestyle intervention for people with impaired
  • glucose tolerance: 30-year results of the Da Qing Diabetes
  • Prevention Outcome Study [J]. Lancet Diabetes Endocrinol, 2019,
  • 7(6): 452-61.
  • [18] HAW J S, GALAVIZ K I, STRAUS A N, et al. Long_xfffe_term Sustainability of Diabetes Prevention Approaches: A
  • Systematic Review and Meta-analysis of Randomized Clinical
  • Trials [J]. JAMA Intern Med, 2017, 177(12): 1808-17.
  • [19] LI B, CHEN L, HU X, et al. Association of Serum Uric
  • Acid With All-Cause and Cardiovascular Mortality in Diabetes [J].
  • Diabetes Care, 2023, 46(2): 425-33.
  • [20] HE Y, FENG J, ZHANG B, et al. Serum uric acid levels
  • and risk of cardiovascular disease in type 2 diabetes: results from
  • a cross-sectional study and Mendelian randomization analysis [J].
  • Front Endocrinol (Lausanne), 2023, 14: 1251451.
  • [21] YANG T, LIU Y, LI L, et al. Correlation between the
  • triglyceride-to-high-density lipoprotein cholesterol ratio and
  • other unconventional lipid parameters with the risk of prediabetes
  • and Type 2 diabetes in patients with coronary heart disease: a
  • RCSCD-TCM study in China [J]. Cardiovasc Diabetol, 2022,
  • 21(1): 93.
  • [22] MALMSTEDT J, KÄRVESTEDT L, SWEDENBORG J,
  • et al. The receptor for advanced glycation end products and risk of
  • peripheral arterial disease, amputation or death in type 2 diabetes:
  • a population-based cohort study [J]. Cardiovasc Diabetol, 2015,
  • 14: 93.
  • [23] PARK J H, SUH D H, KIM H J, et al. Role of
  • procalcitonin in infected diabetic foot ulcer [J]. Diabetes Res Clin
  • Pract, 2017, 128: 51-7.
  • [24] OZER BALIN S, SAGMAK TARTAR A, UĞUR K, et
  • al. Pentraxin-3: A new parameter in predicting the severity of
  • diabetic foot infection? [J]. Int Wound J, 2019, 16(3): 659-64.
  • [25] METINEREN H, DÜLGEROĞLU T C. Comparison of
  • the Neutrophil/Lymphocyte Ratio and C-Reactive Protein Levels
  • in Patients With Amputation for Diabetic Foot Ulcers [J]. Int J Low
  • Extrem Wounds, 2017, 16(1): 23-8.
  • [26] ZUBAIR M, AHMAD J. Role of growth factors and
  • cytokines in diabetic foot ulcer healing: A detailed review [J]. Rev
  • Endocr Metab Disord, 2019, 20(2): 207-17.
  • [27] RUPAIMOOLE R, SLACK F J. MicroRNA therapeutics:
  • towards a new era for the management of cancer and other diseases
  • [J]. Nat Rev Drug Discov, 2017, 16(3): 203-22.
  • [28] MOHAMMEDI K, WOODWARD M, MARRE M, et al.
  • Comparative effects of microvascular and macrovascular disease
  • on the risk of major outcomes in patients with type 2 diabetes [J].
  • Cardiovasc Diabetol, 2017, 16(1): 95.
  • [29] FIORDALISO F, CLERICI G, MAGGIONI S, et al.
  • Prospective study on microangiopathy in type 2 diabetic foot ulcer
  • [J]. Diabetologia, 2016, 59(7): 1542-8.
  • [30] MOHAMMEDI K, WOODWARD M, HIRAKAWA Y, et
  • al. Microvascular and Macrovascular Disease and Risk for Major
  • Peripheral Arterial Disease in Patients With Type 2 Diabetes [J].
  • Diabetes Care, 2016, 39(10): 1796-803.
  • [31] LÜDERS F, BUNZEMEIER H, ENGELBERTZ C, et
  • al. CKD and Acute and Long-Term Outcome of Patients with
  • Peripheral Artery Disease and Critical Limb Ischemia [J]. Clin J
  • Am Soc Nephrol, 2016, 11(2): 216-22.
  • [32] SANDHOLM N, GROOP P H. Genetic basis of diabetic
  • kidney disease and other diabetic complications [J]. Curr Opin
  • Genet Dev, 2018, 50: 17-24.
  • [33] SIMÓ R, HERNÁNDEZ C. Neurodegeneration in the
  • diabetic eye: new insights and therapeutic perspectives [J]. Trends
  • Endocrinol Metab, 2014, 25(1): 23-33.
  • [34] SINGHANIA N, BANSAL S, MOHANDAS S, et al. Role
  • of renin-angiotensin-aldosterone system inhibitors in heart failure
  • and chronic kidney disease [J]. Drugs Context, 2020, 9.
  • [35] LIU G, LI Y, PAN A, et al. Adherence to a Healthy
  • Lifestyle in Association With Microvascular Complications Among
  • Adults With Type 2 Diabetes [J]. JAMA Netw Open, 2023, 6(1):
  • e2252239.
  • [36] GENG T, ZHU K, LU Q, et al. Healthy lifestyle
  • behaviors, mediating biomarkers, and risk of microvascular
  • complications among individuals with type 2 diabetes: A cohort
  • study [J]. PLoS Med, 2023, 20(1): e1004135.
  • [37] ZHAO S, LI Y, SU C. Assessment of common risk
  • factors of diabetes and chronic kidney disease: a Mendelian
  • randomization study [J]. Front Endocrinol (Lausanne), 2023, 14:
  • 1265719.
  • [38] PERRY J R, WEEDON M N, LANGENBERG C, et al.
  • Genetic evidence that raised sex hormone binding globulin (SHBG)
  • levels reduce the risk of type 2 diabetes [J]. Hum Mol Genet, 2010,
  • 19(3): 535-44.
  • [39] WONG T Y, CHEUNG C M, LARSEN M, et al. Diabetic
  • retinopathy [J]. Nat Rev Dis Primers, 2016, 2: 16012.
  • [40] SONG K H, JEONG J S, KIM M K, et al. Discordance
  • in risk factors for the progression of diabetic retinopathy and
  • diabetic nephropathy in patients with type 2 diabetes mellitus [J].
  • J Diabetes Investig, 2019, 10(3): 745-52.
  • [41] JENSEN E T, RIGDON J, REZAEI K A, et al.
  • Prevalence, Progression, and Modifiable Risk Factors for Diabetic
  • Retinopathy in Youth and Young Adults With Youth-Onset Type
  • 1 and Type 2 Diabetes: The SEARCH for Diabetes in Youth Study
  • [J]. Diabetes Care, 2023, 46(6): 1252-60.
  • [42] F E R N A N D E S S I L V A L , H O K K A N E N J ,
  • VANGIPURAPU J, et al. Metabolites as Risk Factors for Diabetic
  • Retinopathy in Patients With Type 2 Diabetes: A 12-Year Followup Study [J]. J Clin Endocrinol Metab, 2023, 109(1): 100-6.
  • [43] YIN L, ZHANG D, REN Q, et al. Prevalence and risk
  • factors of diabetic retinopathy in diabetic patients: A community
  • based cross-sectional study [J]. Medicine (Baltimore), 2020, 99(9):
  • e19236.
  • [44] LIU L, YUE S, WU J, et al. Prevalence and risk factors
  • of retinopathy in patients with or without metabolic syndrome: a
  • population-based study in Shenyang [J]. BMJ Open, 2015, 5(12):
  • e008855.
  • [45] GONG D, FANG L, CAI Y, et al. Development and
  • evaluation of a risk prediction model for diabetes mellitus type
  • 2 patients with vision-threatening diabetic retinopathy [J]. Front
  • Endocrinol (Lausanne), 2023, 14: 1244601.
  • [46] MOONS K G, ALTMAN D G, VERGOUWE Y, et al.
  • Prognosis and prognostic research: application and impact of
  • prognostic models in clinical practice [J]. Bmj, 2009, 338: b606.
  • [47] MOONS K G, KENGNE A P, WOODWARD M, et al.
  • Risk prediction models: I. Development, internal validation, and
  • assessing the incremental value of a new (bio)marker [J]. Heart,
  • 2012, 98(9): 683-90.
《中国学术期刊(光盘版)》电子杂志社有限公司 KDN平台基础技术由KBASE 11.0提供
© 2014-2018中国知网(CNKI) 京公网安备11010802020460号 经营性网站备案信息 互联网出版许可证 新出网证(京)字271号 京ICP证040431号